Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.

ABSTRACT: Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatment, including the human epidermal growth factor 2 positive (HER2+) subtype. The immune system holds the ability to spontaneously implement a defensive response against HER2+ BC cells through complex mechanisms which can be exploited to modulate this response for obtaining a clinical benefit. Initial immune system modulating strategies consisted mostly in vaccine therapies, which are still being investigated and improved. However, the entrance of trastuzumab into the scenery of HER2+ BC treatment was the real game changing event, which embodied a dominant immune-mediated mechanism. Mo

SUBMITTER: Krasniqi E 

PROVIDER: S-EPMC6820969 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature